MarginsXMarginsX
Home › Markets › Health Care › KAPA

Kairos Pharma Ltd. (KAPA)

KAPA trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.4069
-10.30% on the day
Market cap
$1.4M
Nano cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerKAPA on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryNot reported by the screener
IPO year2024
SEC CIK0001962011

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
7.9 months
$2.6M cash at June 30, 2026
Share count, 1 year
+57.5%
2025-11-14 to 2026-11-13
Going-concern doubt
Yes
10-Q filed November 13, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors raise substantial doubt about the Company's ability to continue as a going concern."
10-Q 2026-11-13
Cash and burn$2.6M cash; operating cash flow -$993K a quarter.Report 2026-06-30
Shares outstanding4,685,025 (2026-11-13); 20,821,353 a year earlier. 1y figure adjusted for split (1-for-7 overall).Cover page 2026-11-13
Reverse splits, 3 years1; latest 1-for-7 on 2026-09-01Source 2026-09-01
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-01-13
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorWeinberg & Company, P.A., Los Angeles, California, United States; changed auditors 1 time in 24 months8-K 4.01 2025-04-28
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$1.4M-$1.0M$2.6MNo debt tagsNeeds four quarters10-Q 2026-08-12
Q1 2026
2026-03-31
Not filed-$1.7M-$1.0M$3.7MNo debt tagsNeeds four quarters10-Q 2026-05-13
Q4 2025
2025-12-31
Not filed-$1.4M-$1.1M$4.5MNo debt tagsNeeds four quarters10-K 2026-03-31
Q3 2025
2025-09-30
Not filed-$1.4M-$838K$5.6MNo debt tagsNeeds four quarters10-Q 2025-11-14
Q2 2025
2025-06-30
Not filed-$1.4M-$805K$3.0MNo debt tagsNeeds four quarters10-Q 2026-08-12
Q1 2025
2025-03-31
Not filed-$1.3M-$714K$3.6MNo debt tagsNeeds four quarters10-Q 2026-05-13
Q4 2024
2024-12-31
Not filed-$980K-$1.8M$1.3MNo debt tagsNeeds four quarters10-K 2026-03-31
Q3 2024
2024-09-30
Not filed-$1.0M-$2.0M$3.2MNo debt tagsNeeds four quarters10-Q 2025-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week-7.0%
1 month-45.2%
3 months-82.0%
Year to date-90.9%
1 year-91.8%
From 52-week high-93.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ELABPMGC Holdings Inc.$1.66+5.06%$1.3M
APVOAptevo Therapeutics Inc.$0.5486-7.66%$1.5M
ARTLArtelo Biosciences Inc.$1.70-17.87%$1.6M
BDRXBiodexa Pharmaceuticals plc American Depositary Shs$2.24-6.28%$1.2M
ENLVEnlivex Ltd.$1.12-5.88%$1.7M
GOVXGeoVax Labs Inc.$2.02+18.48%$1.1M
SXTP60 Degrees Pharmaceuticals Inc.$0.4938-4.65%$1.7M
HCWBHCW Biologics Inc.$0.8000+3.48%$1.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier